Research and Markets: Riding the Biotech Economic Tsunami - Surfing to Safety or Wipeout?

12-Jun-2009 - Ireland

Research and Markets has announced the addition of Decision Resources, Inc.'s new report "Riding the Biotech Economic Tsunami - Surfing to Safety or Wipeout?" to their offering.

In 2008, the global financial crisis radically altered the dynamics of the biotech industry; many weaker companies will fail. However, private investment in biotech continued, and pharmaceutical companies invested significant sums in acquiring and partnering with biotech companies offering innovative products and technologies for drug discovery.

Questions Answered in This Report:

- Although the state of the economy is the dominant parameter that affects all industries, the biotech industry is especially sensitive to economic fluctuations. How are declines in capital markets affecting the biotech industry? What are the current trends in biotech IPO activity?

- Despite the economic downturn, venture capital (VC) firms continued to invest in biotechnology in 2008. What types of biotech companies are attracting VC investments? Which technology areas attracted the most investment? What types of start-up companies are able to obtain early-stage financing?

- Mergers and acquisitions (M&As) have long been a litmus test of the strategic objectives of pharmaceutical companies. M&As also have become an important instrument for biotech companies that are seeking to survive or become stronger. What are the current trends in pharma-biotech and biotech-biotech M&As? What factors drove M&A activity in 2008?

- Corporate partnerships with pharmaceutical companies have become supremely important to biotech companies as one of the few remaining sources of reliable capital. What technology areas are attracting the interest of pharmaceutical companies? What deal structures characterize current partnering trends?

https://www.bionity.com/en/news/101969/research-and-markets-riding-the-biotech-economic-tsunami-surfing-to-safety-or-wipeout.html